Oral Suspension
Avadel Pharmaceuticals’ Narcolepsy Drug LUMRYZ Receives FDA Approval and Orphan Drug Exclusivity
Avadel Pharmaceuticals, LUMRYZ, narcolepsy, FDA approval, Orphan Drug Exclusivity, sodium oxybate, extended-release oral suspension
Actionable Insights Powered by AI
Avadel Pharmaceuticals, LUMRYZ, narcolepsy, FDA approval, Orphan Drug Exclusivity, sodium oxybate, extended-release oral suspension